Related Experiment Video
Updated: Apr 4, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Therapeutic update in hepatitis C]
María José Devesa1, Francisca Cuenca, Sonia Izquierdo
1María José Devesa, Servicio de Aparato Digestivo. Hospital Clínico San Carlos, Madrid, Spain. mjdevesa@yahoo.es.
Abstract:
Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing efficacious Interferon-free therapies superior to prior treatment regimens with minimal side effects, even in some subgroups previously thought to be difficult to cure such as cirrhotic patients.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Therapeutic Drug Monitoring: Overview and Classification
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

